Form 4: Aligos Therapeutics Director Nuechterlein Exchanges Stock Options

Director Carole Nuechterlein exchanged stock options in Aligos Therapeutics, canceling an existing option for 15,000 shares and receiving a replacement option for 4,411 shares with a lower exercise price.

Summary

• Carole Nuechterlein, a director of Aligos Therapeutics, engaged in a stock option exchange.
• On February 27, 2024, Nuechterlein's option for 15,000 shares, granted on June 17, 2021, with an exercise price of $26.58, was canceled as part of the issuer's option exchange program.
• On February 28, 2024, Nuechterlein received a replacement option for 4,411 shares with an exercise price of $0.96 per share.
• The new option vests one year from the grant date, contingent upon continued service with Aligos Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a stock option exchange, which is a fairly routine transaction. The lower exercise price on the new options could be seen as slightly positive for the director, but the reduced number of shares balances this out.

Positives

• The new option has a significantly lower exercise price ($0.96) compared to the canceled option ($26.58), potentially increasing its value to the director.
• The option exchange program may be part of a broader strategy to incentivize employees and align their interests with the company's performance.

Negatives

• The number of shares covered by the new option (4,411) is significantly less than the canceled option (15,000).

Industry Context

Option exchange programs are sometimes used by companies to re-incentivize employees, particularly when the stock price has declined significantly since the original options were granted. This can help retain talent and align employee interests with shareholders.

Comparison to Industry Standards

• Option exchange programs are a relatively common practice in the biotech industry, especially for companies whose stock price has fallen below the exercise price of previously granted options.
• Similar programs have been implemented by companies like Gilead and Amgen to refresh employee equity incentives.

Stakeholder Impact

• The option exchange could have a minor positive impact on employee morale by providing a more valuable incentive.
• The impact on shareholders is likely negligible, as the number of shares involved is relatively small.

Key Dates